|Bid||1.0300 x 2900|
|Ask||1.0300 x 900|
|Day's Range||0.9500 - 1.0100|
|52 Week Range||0.7400 - 25.6000|
|Beta (3Y Monthly)||2.77|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Entrepreneurs of all types strive to create new solutions to old problems, and that always comes with risk of failure — and not just with untested drugs. One shouldn’t stop striving to create something new, no matter the industry, just because it might not work out.
“We had a commercial team, a marketing team, and the sales organization. … At the last minute, the FDA decided the data was not sufficient for approval.”
Oncternal does not anticipate retaining any GTx employees once the merger is completed. The biopharmaceutical firm has 27 employees — 25 of them local.
Yesterday, FedEx Logistics, a subsidiary of FedEx Corp., announced plans to move its global headquarters to the former Gibson Guitar Factory building in 2020, joining the likes of some of the area’s largest locally based public companies. To read more on FedEx Logistics and plans for the area, click here, here, or here. This news comes almost exactly a year after home services provider, ServiceMaster Global Holdings relocated its first group of employees from East Memphis to the newly renovated One ServiceMaster Center, formerly the Peabody Place mall.
On a per-share basis, the Memphis, Tennessee-based company said it had a loss of 39 cents. The company's shares closed at $1.79. A year ago, they were trading at $7.92. _____ This story was generated by ...
The more than 50 current and former executives at Memphis-based public companies earned $180 million in total compensation in 2017.
The company's only drug candidate failed a mid-stage clinical trial. The next clinic-ready assets are on the way -- in late 2019 or early 2020.
On a per-share basis, the Memphis, Tennessee-based company said it had a loss of 43 cents. GTx shares have increased 40 percent since the beginning of the year. The stock has more than tripled in the last ...
This was a multicenter, randomized, double blind, placebo controlled trial that enrolled a total of 108 subjects (83 women and 25 men) age ≥ 65 years of age who had suffered a hip fracture within the past three to seven weeks. Subjects were administered placebo or 0.5 mg, 1.0 mg, or 2.0 mg of VK5211 once-daily for 12 weeks (NCT02578095). The primary outcome of the trial was the change in lean body mass, less head, after 12 weeks of treatment.